Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Inflammatory Dynamics of Innate Immune Cells

NCT07633327 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-06-01
Last updated
2026-06-08

Condition(s) studied

Peritoneal Lavage

Investigational drug(s) / intervention(s)

Digestive surgery

Digestive surgery: Routine digestive surgery

Study summary

The proposed clinical research project aims to explore the functional dynamics of innate immune cells in patients. The protocol includes collecting samples from episodes of inflammatory disease, from which fluid will be extracted. The sampling procedure will be carried out non-invasively for the patient. Following collection, the fluid and cells will be separated. The cytokine profile of the fluid will be analyzed using ELISA and flow cytometry to detect inflammatory cytokines in the patient. The isolated cells from the fluid will then be analyzed by flow cytometry and differentially identified based on the physiological state of the patient, as well as to identify the presence of inflammatory markers in these immune cells.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * All patients undergoing digestive surgery from 18 to 80 years old. Exclusion Criteria: * Patients under immunomodulatory treatments

Primary outcome measure(s)

  • Immune cells dynamic — At the inclusion
    Number of cells in each immune cell population, characterization of the composition of each population based on cellular subsets,

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice Alpes-Maritimes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07633327 on ClinicalTrials.gov ↗ ← All trials in France